Drug Development for Select Diseases:

Evidence Based Approach

Based on CCRAS R&D Contributions

Central Council for Research in Ayurvedic Sciences (CCRAS)

Ministry of AYUSH, Govt. of India
Jawahar Lal Nehru Bhartiya Chikitsa Evam Homoeopathy Anusandhan Bhawan
61-65, Institutional Area, Opp. ‘D’ Block, Janakpuri, New Delhi-110058
© 2016, Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India,
New Delhi.

First Edition : June, 2016

No. of Copies : 1000
ISBN : 978-93-83864-20-1

Published by : Central Council for Research in Ayurvedic Sciences (CCRAS),

New Delhi -110058.

Printed at : Dolphin Printo-Graphics

4E/7, Jhandewalan, New Delhi – 110055
www.dolphinprintographics.com

Disclaimer: All possible efforts have been made to ensure the correctness of the contents. However,
CCRAS shall not be accountable for any inadvertent error in the contents. Corrective
measures shall be taken up once such errors are brought to notice.-
 ACKNOWLEDGEMENT
The Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government
of India acknowledges the active participation and technical contribution of the following
officials in the preparation of this document.

Guidance, Facilitation and Chief Editor : Prof. Vd. K. S. Dhiman, Director General,
Central Council for Research in Ayurvedic Sciences, New Delhi.

Executive Editor : Dr. M. M. Padhi, Deputy Director General, Central Council for Research
in Ayurvedic Sciences, New Delhi.

Content Development: Dr. N. Srikanth, Assistant Director (Ayurveda); Dr. Sarda Ota,
Research Officer (Scientist-2); Dr. Shruti Khanduri, Research Officer (Ayurveda); Dr. Renu
Singh, Research officer (Ayurveda); Central Council for Research in Ayurvedic Sciences,
New Delhi.

Technical Support: Dr. Bharti, Assistant Director (Ayurveda); Dr. S. Gaidhani, Assistant
Director (Pharmacology); Dr. A. K. Mangal, Assistant Director (Pharmacognosy); Dr. S.
Singh, Research Officer (Scientist-4); Dr. Sunita, Research Officer (Scientist-2); Dr. B. S.
Sharma, Research Officer (Scientist-2); Dr. V. K. Lavaniya, Research Officer (Ayurveda);
Dr. Chinmay Rath, Research Officer (Botany).

Technical Assistance: Dr. Richa Bhardwaj, Senior Research Fellow(Ayurveda),

Dr. Praveen Sharma, Senior Research Fellow(Ayurveda); Dr. Priyanka, Senior Research
Fellow (Ayurveda).The Council also places record of appreciation to Ms. Meera and
Mr. Pradeep for their secretarial assistance.

Central Council for Research in Ayurvedic Sciences (CCRAS)

iii
 PREFACE
The Central Council for Research in Ayurvedic Sciences has been engaged in clinical
research and drug development of new/ coded formulations based on leads from classical
texts, contemporary scientific and pharmacological leads for important diseases of National
importance based on strength of Ayurveda.

The Council has been putting efforts to translate the research findings into practice
and make available to the needful at large. In this direction, the technologies of new coded
drugs and formulations developed by the Council such as Ayush-64 for Malaria, Ayush-56
for Epilepsy, Ayush-82 for Diabetes mellitus etc have been transferred to the Industry through
National Research Development Corporation, Department of Scientific and Industrial
Research, Ministry of Science & Technology, Government of India.

I am pleased to present this concise and comprehensive document comprising the

fifteen important drugs / formulations developed by the Council through systemic drug
development process such as standardization, Pre Clinical studies and Clinical studies. I
appreciate the effort put in by officers of the Council in developing this document. I sincerely
hope the readers would find this document useful.

(Prof. Vd. K. S. Dhiman)

Director General
Central Council for Research in Ayurvedic Sciences
New Delhi

Central Council for Research in Ayurvedic Sciences (CCRAS)

v
 INDEX

Sl. No. Drugs/ Formulations Page No.

AYUSH -64
1. 1-4
An Ayurvedic anti-Malarial Drug

AYUSH-56
2. 5-6
An Ayurvedic Anti-Epileptic Drug

AYUSH-82
3. 7-9
An Ayurvedic Drug For Diabetes Mellitus

NIMBATIKTAM
4. 10-13
An Ayurvedic Drug For Psoriasis and Duodenal ulcer

AYUSH POSHAK YOGA AND PEYA

5. 14-19
For Immunomodulatory, Antistress and General Health Promotion

SHUNTHI GUGGULU
6. 20-22
For Rheumatoid Arthritis (Amavata)

KSHARASUTRA
7. 23-24
In Ano Rectal Disorders

AYUSH BALARASAYANA
8. 25-26
For Promotion of Health in Children

AYUSH GHUTTI
9. 27-28
For Prevention of Diarrhoea and Fever in Children

AYURVEDIC FORMULATIONS
10. 29-31
For Antenatal Care

Central Council for Research in Ayurvedic Sciences (CCRAS)

vii
 1. AYUSH -64
An Ayurvedic anti-Malarial Drug

Background
Malaria, a tropical diseases is widely prevalent all over the world and has claimed millions of lives.
However, by using modern anti-malarial drugs like quinine, chloroquine & also insecticides to kill
mosquitoes the disease is temporarily controlled. Nevertheless, it has been found that mosquitoes have
developed immunity to the insecticides and their breeding, continues unabated. It has also been realized
that the modern allopathic anti-malarial drugs are highly toxic and their repeated use causes numerous
side- effects resulting in ocular disturbances etc.

Descriptions concerning its aetiopathogenesis, clinical features and line of management are detailed under
‘Vishamajwara’ in ancient classical literature of Ayurveda. Ayurvedic classics vividly recount the sign,
symptoms and phase wise clinical consequences of mosquito bite. This may range from symptoms like
itching, swelling and mild pain to severe form of fever, vomiting etc. Malaria may be comparable to the
clinical entities emerging out of mosquito bite as described in Ayurvedic classics

In order to provide safe, inexpensive and effective remedy for malaria, CCRAS has developed a poly
herbal safe, anti-malarial drug ‘Ayush-64’ through extensive pharmacological, toxicological and clinical
studies. This has been patented by the Council through National Research and Development Corporation,
New Delhi.( Patent No:152863)

Drug Profile
S.No. Ingredients Botanical name Part used
1. Kiratatikta Swertia chirata Buch-Ham. ex Wall. Whole Plant
2. Saptaparna Alstonia scholaris (L.) R.Br Stem Bark
3. Katuki Picrorhiza kurroa Royle ex Benth. Root
4. Kuberaksha Caesalpinia crista L. Seed

Pharmacological/Safety/Toxicity Studies
• In albino mice, oral administration of Ayush -64 at doses of 250-750mg/kg for five days exhibited
significant anti-malarial property.3

• Ayush-64 administered in dose of 500 mg/ kg body weight in rats for 12 weeks was considered safe
and non-toxic. 3

Central Council for Research in Ayurvedic Sciences (CCRAS)

1
AYUSH -64 An Ayurvedic anti-Malarial Drug

Clinical efficacy
• Clinical trials of Ayush-64 were conducted on 1442 positive cases of malaria at various Research
institutes and Centres of the Council located in different part of the country. The response of
treatment was 89% and the findings were comparable with known Anti-malarial drugs-chloroquine
and primaquine.1,2 ,3 (Figure-1).

Figure -1
Source: Ayush-64 A New Ayurvedic Anti- Malarial Compound ,Central Council for Research in Ayurveda & Siddha 1987

Drug Development for Select Diseases: Evidence Based Approach

2
 AYUSH -64 An Ayurvedic anti-Malarial Drug

• OPD & IPD level double blind studies were conducted on 178 patients revealed that the formulation
is effective in 95.4% of patients. Normal temperature besides clearance of malarial parasite was
achieved within 5-7 days. 1,2,3 (Figure-2).

Figure-2
Source: Ayush-64 A New Ayurvedic Anti- Malarial Compound, Central Council for Research in Ayurveda & Siddha 1987

• Collaborative studies with National Malaria Eradication programme (Govt. of Haryana &
Tamil Nadu): These studies conducted on 496 patients have shown clearance of parasites and
clinical improvement in 72-90% in 5-7 days.1,2

• Epidemic Malaria control programme (Western Rajasthan 1984, Assam, 1995) During
epidemic Malarial control programmes at Rajasthan and Assam approximately 3,600 and 10,000
P.vivax cases were treated respectively. Clinical improvement was observed in almost all cases.
Positive P.falciparum was observed in some cases and parasite clearance and clinical improvement
was found in few numbers of cases. 1,2

Side effects: No side/toxic effect in prescribed doses

Central Council for Research in Ayurvedic Sciences (CCRAS)

3
AYUSH -64 An Ayurvedic anti-Malarial Drug

Recommended Dose: As mentioned below or as directed by the physician

Adult : 4 tablets (500 mg each) thrice daily for 5-7 days

Children (5-12 years) : 2 tablets thrice daily for 5-7 days
Infants (below 5 years) : Powder of 1 tablet with honey, three times a day

Ingredients

Katuki (Picrorhiza kurroa Royale) Kuberaksa (Caesalpinia crista Linn.)

Kiratatikta (Swertia chirata Buch-ham) Saptaparna (Alstonia scholaris R.Br)

References
1. Ayush-64 A New Ayurvedic Anti- Malarial Compound ,Central Council for Research in Ayurveda
& Siddha(CCRAS) 1987

2. CCRAS Research an Overview, CCRAS, Year:2002, Page no.35-36

3. A Clinical trial of Ayush-64 (A coded anti-malarial medicine) in case of Malaria, Journal of

Research in Ayurveda and Siddha, CCRAS, Year: 1981, Vol:2, Issue: 1-2, pages 309-326

4. Pharmacological Investigations of certain Medicinal Plants and Compound Formulations used in

Ayurveda and Siddha; Central Council for Research in Ayurveda & Siddha (CCRAS), 1996.

Drug Development for Select Diseases: Evidence Based Approach

4
 2. AYUSH-56
An Ayurvedic Anti-Epileptic Drug

Background
Epilepsy(Apasmara) is a transient loss of consciousness with terrifying physical movements born of
derangement of memory, intellect and mind. Epilepsy is a Greek word meaning “A condition of being
overcome or seized or attached”. The clinical picture of Apasmara presented in Ayurveda and that of
epilepsy in modern medicine are almost identical. Ayurveda considered the involvement of both body and
mind in the causation of the disease. About 30%of the patients of epilepsy do not respond to the current
available modern drugs besides their adverse effects.

In view of this, the Central Council for Research in Ayurvedic Sciences, through extensive pharmacological/
toxicological and clinical studies has evolved a new safe and effective coded drug Ayush-56 for the
management of epilepsy. This has been patented by the Council through National Research and Development
Corporation, New Delhi. (Patent No: 141170)

Drug Profile
S. No. Ingredients Botanical name Parts used
1. Sunisannaka Marsilea minuta L. Whole Plant
2. Jatamansi Nardostachys jatamansi (D. Don) Root/Rhizome
DC.

Safety/Toxicity Profile: Acute and sub-acute toxicity studies revealed no toxic effects of the drug.1

Clinical Efficacy:
Clinical studies on 273 subjects were carried out at three peripheral research Institutes/Units of the
Council to ascertain the efficacy of Ayush-56 in the treatment of Epilepsy (Apasmara). The study showed
significant reduction (65%) in frequency and duration of epileptic fits. It is found useful as an add on
therapy to the modern anti-epileptic treatment. No adverse event in prescribed doses was reported. Further,
no withdrawal effect was observed after slowly tapering the modern medicine with this drug.2,3. The overall
effect of the drug Ayush-56 is given in the Table-1.
Table- 1: Showing the overall effect of the drug Ayush-56 (n = 273)
Sl. No. Result No. of cases
1. Complete control 87
2. Marked control 48
3. Moderate control 41
4. No control 97
Central Council for Research in Ayurvedic Sciences (CCRAS)
5
AYUSH-56 An Ayurvedic Anti-Epileptic Drug

Recommended Dose

Adults : Two tablets (250 mg each), three times a day for six months or as directed by physician
Children : One tablet (250 mg each), three times a day for six months or as directed by physician

Ingredients

Jatamansi (Nardostachys jatamansi DC. )

Sunisannaka (Marsilea minuta Linn)

REFERENCES
1. Pharmacological Investigations of certain Medicinal Plants and Compound Formulations
used in Ayurveda and Siddha; Central Council for Research in Ayurveda & Siddha (CCRAS),
1996.

2. CCRAS Research an Overview; Central Council for Research in Ayurveda & Siddha
(CCRAS), Year: 2002, Page no. 22-23.

3. Ayush-56 An Ayurvedic Anti- Epileptic Drug; Central Council for Research in Ayurveda &
Siddha (CCRAS), 1997.

Drug Development for Select Diseases: Evidence Based Approach

6
 3. AYUSH-82
An Ayurvedic Drug for Diabetes Mellitus

Background
Diabetes mellitus (Madhumeha) is a group of metabolic diseases marked by high level of blood glucose
resulting from defects in insulin production, insulin action or both. Diabetes may lead to serious
complications involving multiple organs. Ayurvedic literatures vividly describe about the aetiology,
pathogenesis, prognosis, complications, its management and scientifically attributed the causal relationship
of dietary, lifestyle, environmental and genetic factors.

CCRAS has developed a polyherbal formulation, Ayush-82 for the management of Diabetes mellitus.

Drug Profile
Sl.No. Drug name Botanical/English name Part used
1. Jambu Syzygium cumini (L.) Skeels Seed
2. Karvellaka Momordica charantia Linn. Seed
3. Meshashringi Gymnema sylvestre R.Br. Leaf

4. Amra Mangifera indica Linn. Seed

Safety/toxicity profile
Acute Toxicity Studies of Ayush-82 administered orally in Swiss Albino (I.B) mice revealed no pre-terminal
deaths, no toxic signs and abnormal behavior in the animals at 10 times of intended therapeutic dose.

Sub-Acute Toxicity Studies of Ayush -82 in Wistar rats showed no significant effect in the blood
biochemistry, haematology and weight of the vital organs in comparison to the control suggestive of its
safety.

Clinical efficacy
The study has been carried out on 886 patients (497 completed cases and 389 drop outs) at Council’s
peripheral Central Research Institutes wherein Ayush-82 was administered thrice daily. The results
indicate statistically significant reduction in fasting and post prandial blood sugar level along with clinical
improvement. No adverse events were reported during the treatment period1,2,3,4.

Central Council for Research in Ayurvedic Sciences (CCRAS)

7
AYUSH-82 An Ayurvedic Drug For Diabetes Mellitus

Figure-3

Recommended Dose
15 g per day in 3 divided doses along with 500 mg Shuddha Shilajita twice daily3,4.

Ingredients

Jambu (Syzygium cumini (L.) Skeels) Meshashringi (Gymnema sylvestre R.Br)

Amra (Mangifera indica Linn.) Karvellaka (Momordica charantia Linn.)

Drug Development for Select Diseases: Evidence Based Approach

8
 AYUSH-82 An Ayurvedic Drug For Diabetes Mellitus

References:
1. CCRAS Research an Overview, Central Council for Research in Ayurveda & Siddha (CCRAS),
Year:2002, Page no. 21.

2. Annual Report of Central Council for Research in Ayurveda & Siddha (CCRAS), 1982-2007.

3. Hypoglycemic effect of a coded formulation : Ayush-82, D.P.Chowdhary et al, JRAS, Vol. XIX, no.
3-4,(1998) pp.107-115.

4. An effective Ayurvedic hypoglycaemic formulation, V.N.Pandey et al, JRAS, Vol. XVI, no.
1-2,(1995) pp.1-14.

Central Council for Research in Ayurvedic Sciences (CCRAS)

9
 4. NIMBATIKTAM
An Ayurvedic Drug for Psoriasis and Duodenal ulcer

Background
Nimba is one of the most commonly used plant in Ayurveda. Ayurveda mentions the therapeutic use
of it’s fruits, seeds, seed oil, stem bark, leaves & flowers. Ayurveda classics advocate the use of seed
oil in various disease conditions like skin disease, ulcers, diabetes, fever etc. Owing to its therapeutic
importance, Central Council for Research in Ayurvedic Sciences has developed Nimbatiktam , the major
bitter component obtained from the seed oil of Nimba (Azadirachta indica A. Juss. ) . The Council has
conducted studies of Nimbatiktakam for its efficacy in Psoriasis and Duodenal Ulcer

Drug Profile

Ingredients Botanical name Part used

Nimba Azadirachta indica A. Juss Seed Oil

Safety/toxicity profile:
In albino rats and mice acute toxicity studies, Nimbatiktam showed no toxicity up to 2000 mg/kg orally
and 1000mg/kg intra peritoneally. Sub acute toxicity studies in albino rats up to 100 mg/kg daily for 6
weeks and 10 and 20 mg/kg orally in dogs for 4 weeks did not reveal any systemic toxicity. Teratogenic
studies in rats also did not reveal any toxic manifestations or foetal abnormalities.1

I. NIMBATIKTAM FOR PSORIASIS

Clinical efficacy
 Nimbatiktam with Lajjalukeram
A combination of internal administration of Nimbatiktam 200 mg twice daily and Lajjalukeram as external
application for 60 days were taken for trial at Councils peripheral institute. The trial has been conducted on
386 patients and about 56% of the patients have shown good and fair response.2,3

 Nimbatiktam with Aragwadha kera

A double blind clinical study was carried out on 40 patients randomly grouped into 2 groups (20 in each)
at Council’s peripheral institute to assess the therapeutic activity of Nimbatiktam in Psoriasis (Discoid
Psoriasis). One group was treated with Nimbatiktam 200 mg capsule twice daily and the other group with

Drug Development for Select Diseases: Evidence Based Approach

10
 NIMBATIKTAM An Ayurvedic Drug for Psoriasis and Duodenal ulcer

Lactose (Placebo) 200 mg capsule orally for 60 days and Aragwadha kera 50 ml for external application
daily in both the groups. This double-blind study proved that the effect of Nimbatiktam in the treatment of
psoriasis is statistically significant at 5% level. P<0.05 than the placebo.4

Case Report: A 60 year old male patient with well defined psoriatic lesions and no complication was
administered Nimbatiktam 100mg (Capsule) thrice daily orally and 1g Nimbatiktam mixed in 100 g of
Coconut oil externally for 72 days. The patient recovered from all the symptoms of Psoriasis.5

II. NIMBATIKTAM FOR DUODENAL ULCER

Pharmacological Profile:
Antiulcer effects6

• In rats, Nimbatiktam in 20 mg/kg dose level given orally, exhibited significant protection (P<0.001)
against Shay ulcers in rats. Significant reduction was observed in both free and total acid output
(P<0.001) and peptic activity (P<0.05) of the gastric fluid. At 80 mg/kg daily for 10 days it showed
significant (P<.05) reduction in ulcer index with a healing rate of 57.8% in acetic acid induced
gastric ulcers in rats. The drug significantly suppressed the chronic glandular stomach lesions
induced by steroid in rats. The test drug also significantly suppressed serotonin (SHT) induced
gastric ulcers in rats.

• In guinea pigs, Nimbatiktam in 20 mg and 40 mg/kg doses administered orally gave significant
(P<0.01) protection against histamine ulceration. At 40mg/kg dose, the intensity of ulceration was
considerably reduced and ulcer score was observed to be lower than the controls(P<0.001). The
test drug showed significant(P<0.02) antipeptic activity.

• In histamine-induced duodenal ulcers in guinea pigs, Nimbatiktam at 80 mg/kg prior to histamine,

significantly (P<.01) reduced ulcer incidence and severity.

• In mongrel dogs, oral dosing of Nimbatiktam (10 & 20 mg/kg) for 28 days significantly accelerated
the healing of acetic acid induced chronic gastric ulcers. It significantly prevented gastric lesions
induced by non-steroidal anti-inflammatory compounds (NOSAC) like aspirin (ASA) and
indomethacin and this effect was more marked at the higher dose level of 80 mg/kg.

The drug in 20 mg/kg dose level (p.o) was found to have significant anti ulcer activity in shay ulcers
in rats and histamine ulcer in guinea pigs. The same dose had significant anti peptic activity in rats and
guinea pigs. However, 40 mg/kg dose possessed anti-secretary effect in shay rats. The ulcer healing
effect of Nimbatiktam could be attributed to its antisecretary and anti-peptic activity associated with an
enhancement of local healing process.

Central Council for Research in Ayurvedic Sciences (CCRAS)

11
NIMBATIKTAM An Ayurvedic Drug for Psoriasis and Duodenal ulcer

Clinical efficacy
 Nimbidin Extract 100 mg was administered twice daily in 13 cases of active duodenal ulcer for 60
days. Ulcer completely healed as observed in the review endoscopy in 3 patients, ulcer healing was
in process in 5 patients, no healing effect was observed in 5 patients at the end of trial.7

 Nimbatiktam 150 mg was administered thrice daily with water for 30 days at Council’s peripheral
institute. The results seem quite significant as 16 (40%) cases had relief of more than 75% and
4(10%) cases had moderate relief ( 51%-74%).8

Recommended Dose
• For Psoriasis : Nimbatiktam 200mg twice daily orally for 60 days along with external application
lajjalu kera or Aragwadha kera

• For Duodenal ulcer: Nimbatiktam 100mg-150 mg twice or thrice daily orally for 30-60 days

INGREDIENT OF NIMBATIKTAM

Nimba (Azadirachta indica A. Juss)

References
1. Pillai N.R et al “Toxicity studies on Nimbidin (Nimbatiktham), a potential anti ulcer drug”. Planta
Medica , Vol. 50, No.2, 1984, pg 146-148.

2. CCRAS Research an Overview, Central Council for Research in Ayurveda & Siddha (CCRAS),
Year: 2002, Page no.48.

3. Annual Report of Central Council for Research in Ayurveda & Siddha (CCRAS), Year 1981-1999

4. B.K.R. Pillai, et.al. , “The effect of Nimbathiktha (Nimbidin) in Kitibha (Psoriasis)-A double blind
clinical study”, J.R.A.S. Vol. XXIII, No. 1-2, (2002), pp.42-50.

Drug Development for Select Diseases: Evidence Based Approach

12
 NIMBATIKTAM An Ayurvedic Drug for Psoriasis and Duodenal ulcer

5. Rajasekharam S et.al., Effect of Nimbidin in Psoriasis, A Case Report , JRAS, Vol.1 No.1,
P-52-58( 1982)

6. Pillai N.R. et.al Anti-Gastric Ulcer Activity of Nimbidin, Indian J Med Res 68, July 1978, pp
169-175

7. K.V.Devidas et.al., Effect of Nimbidin in the treatment of Parinamasula, J.R.A.S. Vol.XX,

No.3-4, (1999) pp.187-190

8. Padhi MM et.al. “Effect of Nimbatiktam in the management of Parinamashula: A Clinical

evaluation”, JRAS Vol.XXI,No.3-4,(2000) pp.103-111

Central Council for Research in Ayurvedic Sciences (CCRAS)

13
 5. AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

Background
Ayurveda emphasizes on prevention of disease and improve the quality of health as well as life span.
A number of medicinal plants have been recommended for this purpose. These plants provide specific
resistance and make the body strong to counteract any adverse physical, chemical or biological stress.

The people belonging to Antarctica region are exposed to environmental stress viz. cold, mental and
nutritional stress including others factors like radiations, food preservatives etc. which generate free-
radicals in the body thus suppressing the immune system and causing early ageing. To combat such
adverse situations, Council developed Ayush poshak yoga and peya for improving general well being.

Drug profile
Ayush Poshak Yoga

Sl.No Name Botanical/English name Part Used

1. Kaju Anacardium occidentale L. kernel
2. Badam Prunus amygdalus Stokes kernel
3. Pista Pistacia vera L. kernel
4. Akhrot Juglans regia L. Cotyledons
5. Khas khas Papaver somniferum L. Seeds
6. Safed musli Chlorophytum tuberosum (Roxb.) Baker Tuberous root
7. Pumpkin Cucurbita pepo L. Seed
8. Trapush Cucumis sativus L. Seed
9. Tarbooj Citrullus vulgaris Schrad. Seed
10. Kharbooj Cucumis melo var.Utilissimus Dutt & Fueller Seed
11. Shunthi Zingiber officinale Rosc. Rhizome
12. Pippali Piper longum L. Fruit
13. Maricha Piper nigrum L. Fruit
14. Aswagandha Withania somnifera (L.) Dunal. Root
15. Saunf Foeniculum vulgare Mill. Fruit
16. Guduchi Tinospora cordifolia (Willd.) Miers Stem
17. Sita Sugar Candy -

Drug Development for Select Diseases: Evidence Based Approach

14
 AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

Ayush Poshak Peya

Sl. No. Sanskrit / Local Name Botanical name Part Used
1. Tea Leaf Camellia sinensis (L.) O.Kuntze Leaf
2. Sukshmaila Elettaria cardamomum Maton Seed
3. Tvak Cinnamomum verum Breyn. Stem bark
4. Kumkuma Crocus sativus L. Style & Stigma
5. Arjuna Terminalia arjuna (Roxb.) Wight & Arn. Stem bark

Clinical efficacy
The combined intake of Ayush Poshak Yog and Peya helped in the management of stress related symptoms
as evident by notable changes in immunoglobulin level and antioxidant enzymes. The formulations
significantly improved quality of life of individuals. 1, 2

Effect of APY and APP on igA Effect of APY and APP on igG

Effect of APY and APP on igM

Central Council for Research in Ayurvedic Sciences (CCRAS)

15
AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

Effect of APY and APP on Catalaes Effect of APY and APP on Malondladohyde (MDA)

Effect of APY and APP on Vitamin E Effect of APY and APP on

Suparoxldedismutase (SOD)

Source: Unpublished technical dossier on Ayush Poshak Yoga and Peya(CCRAS).

Recommended Dose
• Ayush Poshak Yoga 45-50gm.

• Ayush Poshak Peya 125-150 ml.

Drug Development for Select Diseases: Evidence Based Approach

16
 AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

SOME IMPORTANT INGREDIENTS OF AYUSH POSHAK YOGA

Badam (Prunus amygdalus Batsch) Kaju (Anacardium occidentale Linn)

Akhrot (Juglans regia Linn.) Pista (Pistacia vera Linn.) Saunf (Foeniculum vulgare Mill.)

Ashwagandha (Withania somnifera (L.) Dunal.) Guduchi (Tinospora cordifolia (Willd) Miers)

Central Council for Research in Ayurvedic Sciences (CCRAS)

17
AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

Ingredients of Ayush Poshak Peya:

Tea Leaf (Camellia sinensis) (L.) O. Kuntze Sukshmaila (Flettaria cardamomum Maton)

Tvak (Cinnamomum verum Breyn.) Kumkuna (Crocus sativus L.)

Arjun (Terminalia arjuna (Roxb.) Wight & Arn)

Drug Development for Select Diseases: Evidence Based Approach

18
 AYUSH POSHAK YOGA AND PEYA
For Immunomodulatory, Antistress and General Health Promotion

References
1. P.Bansal et.al., Effect of certain established Ayurvedic Rasayana Food Supplements on Aging
Process at Antarctica –A Review, Indian Antarctic Expedition Ministry of Earth Sciences,
Technical Publication no. 21 ,PP 361-375|Edition-23rd |.

2. P.Bansal et.al., Effect of Traditionally Designed Nutraceutical on Stress Induced Immunoglobulin

Changes at Antarctica, African Journal of Biochemistry Research,|Year :April 2009|Volume :3(4)|
PP :084-088|.

Central Council for Research in Ayurvedic Sciences (CCRAS)

19
 6. SHUNTHI GUGGULU
For Rheumatoid Arthritis (Amavata)

Background
Rheumatoid Arthritis (Amavata) is an autoimmune inflammatory disease that causes pain, swelling,
stiffness, destruction, and functional disability in the affected joints. In chronic cases, the disease may
cause deformity and total incapacitation. Descriptions concerning aetiopathogenesis, clinical features and
line of management are detailed under Amavata in Ayurveda. According to Ayurveda, the main cause of
the disease is formation of Ama due to Agnimandya i.e gastrointestinal dysfunction.

The cardinal features of Amavata are swelling and severe pain that seems to be of scorpion bite over the
joints and other symptoms include body pain, loss of appetite, excessive thirst, laziness, heaviness of the
body and fever. The general principles of treatment of this disease in Ayurveda lay emphasis on stimulating
and normalizing the impaired Agni for the correction of digestion and metabolism. Based on the cardinal
features and other associated features, use of different herbal, herbo-mineral preparations & regimens are
described in Ayurvedic classics. CCRAS has developed a herbal safe Ayurvedic Drug Shunthi Guggulu
for Rheumatoid Arthritis (Amavata) through a series of clinical studies.

Drug Profile
Sl. No. Ingredient Botanical Name Part Used
1. Shunthi Zingiber officinale Rosc. Rhizome
2. Guggulu Commiphora wightii (Arn.) Bhandari Gum resin

Clinical efficacy
Multicentre observational study revealed satisfactory improvement of symptoms viz. reduction in pain,
morning stiffness, swelling in joints besides reduction in ESR levels. The observations made on 497
patients showed that about 2/3rd patients (67%) have very good effect under a course of 6 weeks treatment.
General functional capability and improvement in general condition of the patients was noticed.1, 2, 3,

The clinical study was conducted at then CRI, Bhubaneswar on 63 patients of Amavata (Rheumatoid
arthritis) recruited into 2 groups viz. Group-A (Shunthi Guggulu) & Group-B (Yogaraja guggulu, Amavata-
Rasa/ Vatagajankusha-rasa & Maharasanadi-kwatha).

Drug Development for Select Diseases: Evidence Based Approach

20
 SHUNTHI GUGGULU For Rheumatoid Arthritis (Amavata)

The result indicated better effect of Shunthi guggulu (Group-A) as compared to the other set of medicines
(Group-B) Figure-1. 2

Figure-1
Source: Prem Kishore et.al., Clinical Studies on the treatment of Amavata-Rheumatoid Arthritis with
Shunthi-Guggulu, JRAS, 1988 vol.3, No3 & 4, pp-133-146).

The observations in another clinical trial of Shunthi-Guggulu on 50 patients of Amavata-Rheumatoid

Arthritis showed significant effect as about 80% of the patients who completed full course of treatment
showed either marked or complete relief (table-1).3

S. No. Results No. Of cases

1. Complete relief 13
2. Marked relief 19
3. Moderate relief 5
4. Mild relief 2
5. No relief -
6. Dropout 1
Total 50

Table-1
Source: Prem Kishore et.al., Further Clinical Evaluation of Shunthi Guggulu in the Treatment of Amavata-
Rheumatoid Arthritis, JRAS, | Year : 1988 |Volume : IX | Issue : 3-4 | Page : -89-104).

Central Council for Research in Ayurvedic Sciences (CCRAS)

21
SHUNTHI GUGGULU For Rheumatoid Arthritis (Amavata)

Recommended Dose
2 gm- 4 g thrice a day for six weeks with warm water.

Ingredients of Shunthi Guggulu

Guggulu (Commiphora wightii) Shunthi (Zingiber officinale)

References:
1. CCRAS Research an Overview, Central Council for Research in Ayurveda & Siddha (CCRAS),
Year:2002, page no.49-50.

2. Prem Kishore et.al., Clinical Studies on the treatment of Amavata-Rheumatoid Arthritis with
Shunthi-Guggulu, JRAS, 1988 vol.3, No3 & 4, pp-133-146).

3. Prem Kishore et.al., Further Clinical Evaluation of Shunthi Guggulu in the Treatment of Amavata-
Rheumatoid Arthritis, JRAS, | Year : 1988 |Volume : IX | Issue : 3-4 | Page : -89-104).

Drug Development for Select Diseases: Evidence Based Approach

22
 7. KSHARASUTRA
In Ano Rectal Disorders
Background
Improper food habits and faulty life styles are the main causes of ill health. This may lead to abnormal
bowel movement, which if persists, causes various ano-rectal diseases. Besides the above, heredity also
has its contribution towards this disease. Commonly occurring ano-rectal diseases are fistula-in-ano, piles
and fissure in-ano. Ayurveda classifies fistula-in ano and piles under Mahagadas (major diseases). The
chronicity and recurrent nature of these diseases leaves physical and psychological agony to the sufferer.

Ksharasutra, a unique para surgical measure is advocated in Ayurveda to treat these disorders. Ksharasutra
involves insertion of a medicated thread into the fistulous tract. It has many advantages over the modern
surgical measure. Application of Ksharasutra is an OPD measure; which does not require hospitalization,
heavy medication and is completely safe with an advantage of simultaneous cutting and healing. Tissue
damage is very less, hence chance of infection is very minimal and rate of recurrence is negligible .It is
economic and minimal invasive and the patients can carry out their routine work during the treatment.
This measure has been very well accepted/ adopted by the practitioners of Ayurveda and such services are
being provided at various clinical facilities of CCRAS in the country.

Drug Profile

Sl.No Ingredients name Botanical Name Part Used

1. Snuhi Euphorbia nerrifolia L. Latex

2. Apamarga Achyranthus aspera L. Whole plant

3. Haridra Curcuma longa L. Rhizome

Clinical efficacy
A study was conducted at Clinical research enquiry on Ksharasutra Therapy (unit of CCRAS) at Institute
of Medical Science, Banaras Hindu University, Varanasi. In this study total 805 patients were registered
and 700 patients (500 non-recurrent cases and 200 recurrent cases) completed the study1.

The Ksharasutra result showed efficacy in almost all patients (98.77%). Out of 700 cases, 691 were
completely cured. Further, out of 200 recurrent cases 197(98.5%) patients were cured without much
difficulty (Figure-1).

Central Council for Research in Ayurvedic Sciences (CCRAS)

23
KSHARASUTRA In Ano Rectal Disorders

The result also revealed that the average Unit Cutting Time(UCT) in the total (n=700) patients was 5.68
days/cm and the average UCT in recurrent (n=200) was 6.55 days/cm (Figure-2).

Figure-1 Result of treatment in regular and recurrent patients. Figure-2 Relative average unit cutting time of regular and
recurrent patients.

Source: Management of Bhagandara (Fistula-in-Ano) with Ksharasutra, Central Council for Research
in Ayurveda & Siddha (CCRAS), Year:1989

Further studies on 395 patients have been conducted in the Council’s peripheral Research Institutes and
386 (97.72%) patients responded to the procedure2.

Ingredients of Kshara Sutra

Snuhi (Euphorbia nerrifolia) Haridra (Curcuma longa) Apamarg (Achyranchus aspera)

References
1. Management of Bhagandara (Fistula-in-Ano) with Ksharasutra, Central Council for Research in
Ayurveda & Siddha (CCRAS), Year:1989.

2. CCRAS Research an Overview, Central Council for Research in Ayurveda & Siddha (CCRAS).

Drug Development for Select Diseases: Evidence Based Approach

24
 8. AYUSH BALARASAYANA
For Promotion of Health in Children

Background
Malnutrition is the underlying contributing factor in about 45% of all child deaths under the age of 5.
It makes children more vulnerable to severe diseases. From the end of the neonatal period and through
the first 5 years of life, the main causes of death are preterm birth complications, intrapartum-related
complications, diarrhoea, pneumonia and malaria. According to WHO, the mortality rate of children under
5 is very alarming. 5.9 million Children under the age of five, died in 2015, at the approximate rate of
16,000 every day.

Ayurveda, the ancient science of life provides utmost focus on promotion & maintenance of health. The
susceptibility of young children towards various infections or diseases is mainly due to their poor immunity.
The Rasayana drugs provide longevity, optimum strength of physique, improves memory and intelligence.

Considering the general ailments affecting the infants and children, the AYUSH BALARASAYANA has
been scientifically developed by the Central Council for Research in Ayurvedic Sciences for promotion
of health in children and patented through National Research and Development Corporation, New Delhi.
( Patent No:196916)

Drug Profile
A. Balarasayana for Health Promotion in Children

Sl. No. Ingredient Botanical /English Name Part used

1. Shatavari Asparagus racemosus Willd. Root
2. Amalaki Emblica officinalis Gaertn Fruit
3. Guduchi Tinospora cordifolia (Willd.) Miers Stem
4. Bhumyamalaki Phyllanthus fraternus G. L. Webster Whole Plant
5. Bala Sida cordifolia L. Root
6. Mandukparni Centella asiatica (L.) Urb. Whole plant
6. Mukta Shukti Bhasma Calcined shell of pearl oyster (Ostrea edulis) Shell

Clinical efficacy
Clinical studies conducted by CCRAS, New Delhi at its various peripheral centres to establish the efficacy
of Balarasayana showed significant improvement in immunity. Also significant improvement in duration

Central Council for Research in Ayurvedic Sciences (CCRAS)

25
AYUSH BALARASAYANA For Promotion of Health in Children

and episodes of excess cry, diarrhoea and vomiting was observed. Highly significant improvement in
episodes of cough/cold and fevers was also observed when compared to placebo.1

Recommended Dose
Balarasayana: 1 tablet (250mg) twice a day up to 5 years of age
2 tablets (250mg) twice a day for more than 5 years of age

Some important ingredients:

Shatavari (Asparagus racemosus) Bala (Sida cordifolia)

Amalaki (Emblica officinalis) Guduchi (Tinospora cordifolia)

References
1. Family Welfare Research Programme, Central Council for Research in Ayurveda & Siddha
(CCRAS) Annual Report 2000-2001.

Drug Development for Select Diseases: Evidence Based Approach

26
 9. AYUSH GHUTTI
For Prevention of Diarrhoea and Fever in Children

Background
Infant mortality rate amounts very high in tropical countries like India due to infantile diarrhoea. In spite
of enormous expenditure incurred to improve health standards of the masses, diarrhoea still poses the
same threat especially in rural areas. Although it is not a deadly disease as such yet due to ignorance, lack
of medical facilities and late treatment ,children suffer heavily and by the time they reach some proper
medical institution the cases turn complicated to the extent of irreversible state.1 Considering the gravity of
the disease, the AYUSH GHUTTI has been scientifically developed by the Central Council for Research
in Ayurvedic Sciences (CCRAS) to prevent diarrhoea and fever in children. This is useful for development
of proper digestion and assimilation as well as prevents the said disease conditions in childhood. The drug
is patented through National Research and Development Corporation, New Delhi.( Patent No:193336)

Drug Profile
 AYUSH - Ghutti (Prevention of Diarrhoea and Fever)
Sl. No. Ingredient Botanical Name Part used
1. Dadima Punica granatum L. Fruit rind
2. Amra Mangifera indica L. Seed Kernel
3. Kamala Nelumbo nucifera Gaertn. Seed Kernel
4. Haritaki Terminalia chebula Retz. Fruit
5. Sunthi Zingiber officinale Rosc. Rhizome
6. Bilwa Aegle marmelos (L.) Correa Fruit pulp
7. Jahar Mohara pisti (Serpentine stone) Calx

Clinical Efficacy

Clinical studies to establish the efficacy of AYUSH Ghutti were carried out at RSSCA, Varanasi.
AYUSH Ghutti was tried in 50 cases each in trial and control group. Significant improvement was noted
in the episodes and duration of diarrhoea and excess cry. Significant improvement in C3 and C4 levels
(enhancement of immunity) was also reported.2

Dosage Schedule
 Ayush – Ghutti: 1 – 3 ml twice a day

Central Council for Research in Ayurvedic Sciences (CCRAS)

27
AYUSH GHUTTI For Prevention of Diarrhoea and Fever in Children

Some Important Ingredients:

Dadima (Punica granatum) Haritaki (Terminalia chebula)

Bilva (Aegle marmelos)

Amra (Mangifera indica)

References
1. Ancient Science of Life, Vol No. III No. 3 January 1984, Pages 136 – 139.

2. Family Welfare Research Programme, Central Council for Research in Ayurveda & Siddha
(CCRAS), Annual Report 2000-2001.

Drug Development for Select Diseases: Evidence Based Approach

28
 10. AYURVEDIC FORMULATIONS
For Antenatal Care

Background
Pregnancy and child birth is a joyful event in every woman’s life. The growing foetus is totally dependent
on its own mother in every aspect. Thus a proper antenatal care would result in a good maternal and foetal
outcome. Any negligence towards her health may lead to untoward effects and thus cause maternal &
foetal complications or even could be fatal.

Ayurveda has described “Garbhini Paricharya” i.e. antenatal care right from conception up to the birth
of the baby. In Ayurveda, antenatal care comprises of Aahar (dietary regimens), Vihara (life style) and
Aushadhi (medicines). In view of the potential of Ayurveda in promoting the health of pregnant women
and foetus, it is high time to mainstream Ayurvedic management. The Central Council for Research in
Ayurvedic Sciences, New Delhi has developed certain formulations viz. AYUSH AG Tablet, AYUSH PG
Tablet, AYUSH GG Tablet and AYUSH AD candy for antenatal care to promote the health of pregnant
women and foetus and to minimize the complications associated with pregnancy and mortality rate of the
mother and foetus.

Drug Profile: 1
1. AYUSH AG Tablet for Promotion of general health of woman and fetal growth

Sl. No. Ingredient Botanical Name Part used

1. Ashwagandha Withania somnifera (L.) Dunal Root
2. Shatavari Asparagus racemosus Willd. Tuber
3. Amalaki Emblica officinalis Gaertn. Fruit
4. Mandur bhasma Calcined iron rust
5. Mukta shukti Bhasma Calcined shell of oyster pearl

2. AYUSH GG tablet for Edema during pregnancy

Sl. No. Ingredient Botanical Name Part used

1. Gokshura Tribulus terrestris L. Fruit

Central Council for Research in Ayurvedic Sciences (CCRAS)

29
AYURVEDIC FORMULATIONS For Antenatal Care

3. AYUSH PG tablet for Pregnancy Induced Hypertension (PIH)

Sl. No. Ingredient Botanical Name Part used

1. Gokshura Tribulus terrestris L. Fruit
2. Punarnava Boerhavia diffusa L. Whole plant

4. AYUSH AD tablet for prevention of Nausea and Vomiting during pregnancy

Sl. No. Ingredient Botanical Name Part used

1. Amalaki Emblica officinalis Gaertn. (Juice/powder of fruit)
2. Draksha Vitis vinifera L. Fruit
3. Ela Elettaria cardamomum Maton Seed

Safety/Toxicity profile:
1. AYUSH AG Tablet

Acute Toxicity Study: No mortality in mice was reported at graded doses of Ayush-AG (100, 200, 500,
1000 and 2000/Kg, P.O).

Sub-Acute Toxicity Study: Sub-Acute studies in 40 albino rats revealed that no significant changes in the
haematology, blood biochemistry and weight of the vital organs in comparison to the control at the graded
dose level of 200, 800 and 1600 mg/Kg continuous up to 15 days were observed.

2. AYUSH PG tablet

Acute Toxicity Study: No mortality in mice was reported at graded doses of Ayush-PG (100, 200, 500,
1000 and 2000/Kg, P.O).

Sub-Acute Toxicity Study:

Sub-Acute studies in 40 albino rats revealed that no significant changes in the haematology, blood
biochemistry and weight of the vital organs in comparison to the control at the graded dose level of 100,
500 and 1000 mg/Kg continuous up to 15 days.

Clinical efficacy
Clinical studies to ascertain the efficacy of above four coded Ayurvedic formulations were carried out by
Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Govt. of India with
technical support from Indian Council of Medical Research (ICMR), Government of India in selected
areas of two districts viz. Mandi & Kangra at Himachal Pradesh. Total 2465 participants were enrolled
in the study. But data of 1746 participants was analyzed. It is observed that the mean of Hb% at baseline
(1st trimester) was 9.78 ± 0.79 and 10.11± 0.77 at the end of treatment which is statistically significant

Drug Development for Select Diseases: Evidence Based Approach

30
 AYURVEDIC FORMULATIONS For Antenatal Care

(p<0.001). Further, significant improvement in various outcome indicators such as minimal complications
during pregnancy, achievement of full term pregnancy and no still birth and neonatal death were observed
in the study. It is interesting to note that birth weight of most of the baby was comparable to standard i.e.
> 2.5 kg, which indicated the effect of interventions on neonatal health.

Dosage Schedule:
A. AYUSH PG (Pregnancy Induced Hypertension): 1 tablet (500 mg) BD for 7 to 15 days with
water

B. AYUSH AD (Prevention of Nausea and Vomiting during pregnancy): To be kept in mouth SOS
but not more than 8 in a day.

C. AYUSH AG Tablet (Promotion of general health of woman and fetal growth): 1 tablet (500
mg) TDS, from 3rd month onwards of pregnancy up to post delivery – 3 months with water.

D. AYUSH GG tablet: 1 tablet (500 mg) BD during 6th to 8th month of pregnancy.

Some Important Ingredients

Ashwagandha (Withania somnifera)

Amalaki (Embica officinalis) Gokshuru (Tribulus terrestris)

Punarnava (Boerrhavia diffusa) Ela (Elettaria cardamomum) Shatavari (Asparagus racemosus)

References
1. Feasibility of Introducing Indian Systems of Medicine (Ayurveda and Siddha) In the National
Reproductive Child Health (RCH) Services at the Primary Health Care (PHC) level – Hand book
for service providers.

Central Council for Research in Ayurvedic Sciences (CCRAS)

31